RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Emmaus Life Sciences Stock

Emmaus Life Sciences EBIT 2024

Emmaus Life Sciences EBIT

-5.58 M USD

Ticker

EMMA

ISIN

US29137T1016

WKN

A2PNWG

In 2024, Emmaus Life Sciences's EBIT was -5.58 M USD, a -257.64% increase from the 3.54 M USD EBIT recorded in the previous year.

The Emmaus Life Sciences EBIT history

YEAREBIT (undefined USD)
2026e4.44
2025e-5.59
2024e-5.58
20233.54
2022-6.59
2021-6.12
2020-0.03
2019-4.51
2018-10.24
2017-7.1
2016-3.77
2015-2.66
2014-3.82
2013-4.2
2012-4.81
2011-5.29
2010-6.51
2009-6.37
2008-5.47
2007-3.27
2006-0.42
2005-0.03
2004-0.26

Emmaus Life Sciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Emmaus Life Sciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Emmaus Life Sciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Emmaus Life Sciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Emmaus Life Sciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Emmaus Life Sciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Emmaus Life Sciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Emmaus Life Sciences’s growth potential.

Emmaus Life Sciences Revenue, EBIT and net profit per share

DateEmmaus Life Sciences RevenueEmmaus Life Sciences EBITEmmaus Life Sciences Net Income
2026e38.04 M undefined4.44 M undefined4.83 M undefined
2025e23.25 M undefined-5.59 M undefined-3.79 M undefined
2024e21.73 M undefined-5.58 M undefined2.52 M undefined
202329.6 M undefined3.54 M undefined-3.73 M undefined
202218.39 M undefined-6.59 M undefined-10.63 M undefined
202120.61 M undefined-6.12 M undefined-15.95 M undefined
202023.17 M undefined-30,000 undefined1.35 M undefined
201922.75 M undefined-4.51 M undefined-54.84 M undefined
20181.32 M undefined-10.24 M undefined-9.6 M undefined
2017130,000 undefined-7.1 M undefined-7.11 M undefined
201690,000 undefined-3.77 M undefined-5.94 M undefined
2015100,000 undefined-2.66 M undefined-3.38 M undefined
2014140,000 undefined-3.82 M undefined-2.66 M undefined
2013130,000 undefined-4.2 M undefined-10.91 M undefined
2012120,000 undefined-4.81 M undefined-3.41 M undefined
2011110,000 undefined-5.29 M undefined-8.87 M undefined
2010640,000 undefined-6.51 M undefined-8.17 M undefined
2009700,000 undefined-6.37 M undefined-8.52 M undefined
2008770,000 undefined-5.47 M undefined-5.37 M undefined
2007240,000 undefined-3.27 M undefined-3.28 M undefined
20060 undefined-420,000 undefined-440,000 undefined
20050 undefined-30,000 undefined-20,000 undefined
20040 undefined-260,000 undefined-270,000 undefined

Emmaus Life Sciences stock margins

The Emmaus Life Sciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Emmaus Life Sciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Emmaus Life Sciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Emmaus Life Sciences's sales revenue. A higher gross margin percentage indicates that the Emmaus Life Sciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Emmaus Life Sciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Emmaus Life Sciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Emmaus Life Sciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Emmaus Life Sciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Emmaus Life Sciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Emmaus Life Sciences Margin History

Emmaus Life Sciences Gross marginEmmaus Life Sciences Profit marginEmmaus Life Sciences EBIT marginEmmaus Life Sciences Profit margin
2026e95.47 %11.68 %12.7 %
2025e95.47 %-24.05 %-16.28 %
2024e95.47 %-25.68 %11.61 %
202395.47 %11.96 %-12.61 %
202285.92 %-35.83 %-57.8 %
202183.94 %-29.69 %-77.39 %
202090.29 %-0.13 %5.83 %
201995.21 %-19.82 %-241.05 %
201837.12 %-775.76 %-727.27 %
201761.54 %-5,461.54 %-5,469.23 %
201688.89 %-4,188.89 %-6,600 %
2015100 %-2,660 %-3,380 %
201442.86 %-2,728.57 %-1,900 %
2013-7.69 %-3,230.77 %-8,392.31 %
2012-16.67 %-4,008.33 %-2,841.67 %
2011-36.36 %-4,809.09 %-8,063.64 %
201078.13 %-1,017.19 %-1,276.56 %
200981.43 %-910 %-1,217.14 %
200879.22 %-710.39 %-697.4 %
200729.17 %-1,362.5 %-1,366.67 %
200695.47 %0 %0 %
200595.47 %0 %0 %
200495.47 %0 %0 %

Emmaus Life Sciences Aktienanalyse

What does Emmaus Life Sciences do?

Emmaus Life Sciences Inc. is an innovative US-American company that develops, produces, and markets medications based on L-Glutamine. The company was founded in 2000 by Dr. Yutaka Niihara, a Japanese researcher who grew up in the USA and received his doctorate from Harvard Medical School. The idea for founding Emmaus Life Sciences arose from the observation of patients with sickle cell anemia, an inherited blood disease. These patients suffer from intense pain attacks caused by the clumping of red blood cells in the body. Dr. Niihara and his colleagues researched the effects of L-Glutamine on these pain attacks and were able to demonstrate that L-Glutamine can significantly reduce the frequency and intensity of the pain attacks. Based on these research results, Emmaus Life Sciences developed the medication "Endari," which was approved by the US-American regulatory authority FDA in 2017. "Endari" is the first medication specifically approved for the treatment of sickle cell anemia. It is intended to reduce the frequency and severity of pain attacks in patients with sickle cell anemia. Since its founding in 2000, Emmaus Life Sciences has expanded significantly. The company now has multiple locations in the USA and employs over 150 employees. Emmaus Life Sciences operates in two business areas: medications and health products. In the medication area, Emmaus Life Sciences focuses on the development of drugs for rare diseases. In addition to "Endari," the company is working on the development of medications for the treatment of mucopolysaccharidosis (MPS) and acid peptidase deficiency (ASM). In the health products area, Emmaus Life Sciences specializes in the production and marketing of dietary supplements. The company has developed a range of products based on L-Glutamine as the active ingredient. These products are intended to support the health of athletes, people with special dietary needs, older adults, and people with certain diseases. Emmaus Life Sciences' products include L-Glutamine powder for daily use, L-Glutamine capsules for athletes and bodybuilders, L-Glutamine for clinical nutrition, and a special L-Glutamine product for people with chronic kidney disease. Emmaus Life Sciences is an innovative company that builds its products on scientifically validated research results. The company specializes in the development of medications and health products that help people improve their health and increase their quality of life. Emmaus Life Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Emmaus Life Sciences's EBIT

Emmaus Life Sciences's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Emmaus Life Sciences's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Emmaus Life Sciences's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Emmaus Life Sciences’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Emmaus Life Sciences stock

How much did Emmaus Life Sciences achieve in EBIT for the current year?

In the current year, Emmaus Life Sciences has achieved an EBIT of -5.58 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Emmaus Life Sciences.

How has the EBIT of Emmaus Life Sciences developed in recent years?

The EBIT of Emmaus Life Sciences has increased by -257.639% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Emmaus Life Sciences?

The EBIT of Emmaus Life Sciences is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Emmaus Life Sciences pay?

Over the past 12 months, Emmaus Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Emmaus Life Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Emmaus Life Sciences?

The current dividend yield of Emmaus Life Sciences is .

When does Emmaus Life Sciences pay dividends?

Emmaus Life Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Emmaus Life Sciences?

Emmaus Life Sciences paid dividends every year for the past 0 years.

What is the dividend of Emmaus Life Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Emmaus Life Sciences located?

Emmaus Life Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Emmaus Life Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Emmaus Life Sciences from 9/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.

When did Emmaus Life Sciences pay the last dividend?

The last dividend was paid out on 9/10/2024.

What was the dividend of Emmaus Life Sciences in the year 2023?

In the year 2023, Emmaus Life Sciences distributed 0 USD as dividends.

In which currency does Emmaus Life Sciences pay out the dividend?

The dividends of Emmaus Life Sciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Emmaus Life Sciences

Our stock analysis for Emmaus Life Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Emmaus Life Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.